Retinal vein occlusion (RVO) is the second most common retinal vascular disease worldwide, following diabetic retinopathy.

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...

Central vision loss from Age-related Macular Degeneration can begin subtly, faces blur, words distort, yet side vision remains intact. An eye specialist explains why early screening after 50 is ...

Ocular Therapeutix said it would release topline data from its Phase 3 superiority clinical trial of its Axpaxli treatment of wet age-related macular degeneration on Tuesday. Detailed data will be ...

Humans develop sharp vision during early fetal development thanks to an interplay between a vitamin A derivative and thyroid hormones in the retina, Johns Hopkins University scientists have found. The ...

New research suggests that GLP-1 medications may lower the risk of age-related macular degeneration, the leading cause of ...

Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.

SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on ...

A new study in The New England Journal of Medicine revealed that the PRIMA brain computer interface (BCI) retinal implant helped people with advanced age-related macular degeneration regain some ...

Psoriasis is a systemic inflammatory disease in which lipid dysregulation contributes to cardiovascular disease. Because abnormal lipid deposition in the retina is a hallmark of age-related macular ...

Treatment options for age-related macular degeneration (AMD) vary depending on whether you have dry or wet macular degeneration, as well as what stage your condition is in: early, intermediate, or ...